SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[EX-99.1 2 v185365_ex99-1.htm]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: EX-99.1 2 v185365_ex99-1.htm
[EX-99.1 2 v185365_ex99-1.htm]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number 3 PART I. FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) F-1] [CERTIFICATION I, Weibing Lu , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company ; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece ssary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION Weibing Lu (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 5 v185379_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v185379_ex32-2.htm]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number
[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number 3 PART I. FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) F-1] [CERTIFICATION I, Weibing Lu , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company ; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece ssary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION Weibing Lu (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 5 v185379_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v185379_ex32-2.htm]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[BIOSTAR PHARMACEUTICALS, ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS XIANYANG, China, May 17, 2010 (Xinhua-PRNewswire-FirstCall) - Q1 2010 revenuereased 66.0% to $12.4 million - Q1 gross margins were 77.0%, a 1,270-basis point improvement - Q1 2010 Non-GAAPjusted netomereased 32.1% to $2.4 million withjusted EPS of $0.09]
BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
[BIOSTAR PHARMACEUTICALS, ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS XIANYANG, China, May 17, 2010 (Xinhua-PRNewswire-FirstCall) - Q1 2010 revenuereased 66.0% to $12.4 million - Q1 gross margins were 77.0%, a 1,270-basis point improvement - Q1 2010 Non-GAAPjusted netomereased 32.1% to $2.4 million withjusted EPS of $0.09]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)
[v185365_ex99-1.htm 2 EX-99.1]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: v185365_ex99-1.htm 2 EX-99.1
[v185365_ex99-1.htm 2 EX-99.1]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: (Original Filing)
[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page Number 3 PART I.FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) F-1nsolidated Balance Sheets of March 31, 2010 and December 31, 2009 F-1nsolidated Statements ofIncome and Othermprehensiveome for the Three Months Ended March 31, 2010 and 2009 F-2nsolidated Statements ofShareholders] [CERTIFICATION I, Weibing Lu , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany ; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances] [CERTIFICATION I, , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact nece ssary to make the statements made, in light of the circumstances under which such] [CERTIFICATION Weibing Lu (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer v185379_ex32-1.htm 5 EX-32.1] [CERTIFICATION (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) v185379_ex32-2.htm 6 EX-32.2]
BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x March 31, 2010 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [ASSETS ACQUISITION AGREEMENT Party A: Shaanxi Biostar Biotech, Ltd. Legal Representative: WANG Ronghua Party B: Xi’an Meipude Bio-Technology Co., Ltd. Legal Representative: SUN Yaomei On March 28, 2010, Party A and Party B again entered into the following agreement concerning Party A’s acquisition of Party B’s assets. A. Party B agrees to transfer all of the technologies and assets of] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]
